Leerink Partnrs Has Bullish Outlook for Nkarta Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share estimate for Nkarta to ($0.37), slightly improving from a previous estimate of ($0.38).
• The consensus target price for Nkarta is currently $13.60, with a majority of analysts rating the stock as a "buy."
• Nkara's stock opened at $2.20, reflecting fluctuations within a fifty-two week range of $1.31 to $6.63.

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Leerink Partnrs increased their Q3 2025 earnings estimates for shares of Nkarta in a research report issued on Wednesday, August 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($0.37) per share for the quarter, up from their prior forecast of ($0.38). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's FY2025 earnings at ($1.48) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.71) EPS, FY2028 earnings at ($1.44) EPS and FY2029 earnings at ($1.04) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.06.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus dropped their price target on shares of Nkarta from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Mizuho dropped their price target on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating on the stock in a research report on Tuesday, June 10th. Needham & Company LLC restated a "buy" rating and issued a $10.00 price target on shares of Nkarta in a research report on Wednesday, August 13th. Wall Street Zen upgraded shares of Nkarta from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, William Blair restated a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Nkarta has an average rating of "Buy" and an average target price of $13.60.

Nkarta Trading Down 1.1%

NASDAQ:NKTX traded down $0.0250 during mid-day trading on Friday, hitting $2.2750. 203,764 shares of the company's stock were exchanged, compared to its average volume of 949,979. The company has a 50 day simple moving average of $1.95 and a 200-day simple moving average of $1.89. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $6.63. The firm has a market capitalization of $161.58 million, a P/E ratio of -1.54 and a beta of 0.72.

Hedge Funds Weigh In On Nkarta

A number of institutional investors have recently modified their holdings of the company. Invesco Ltd. purchased a new position in shares of Nkarta during the fourth quarter valued at approximately $30,000. Wealth Enhancement Advisory Services LLC purchased a new position in Nkarta in the 1st quarter valued at approximately $32,000. Savant Capital LLC purchased a new position in Nkarta in the 2nd quarter valued at approximately $36,000. ProShare Advisors LLC purchased a new position in Nkarta in the 4th quarter valued at approximately $45,000. Finally, CWM LLC grew its stake in Nkarta by 3,437.3% in the 1st quarter. CWM LLC now owns 28,157 shares of the company's stock valued at $52,000 after buying an additional 27,361 shares in the last quarter. 80.54% of the stock is owned by institutional investors and hedge funds.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.